HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)

Subscribe to New Research on Mantle-Cell Lymphoma

A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).

Also Known As:

Lymphoma, Mantle Cell; Lymphoma, Mantle-Cell; Diffuse Lymphocytic Lymphoma, Poorly-Differentiated; Lymphocytic Lymphoma, Diffuse, Poorly Differentiated; Centrocytic Small-Cell Lymphoma; Centrocytic Small-Cell Lymphomas; Diffuse Lymphocytic Lymphoma, Poorly Differentiated; Lymphoma, Centrocytic Small Cell; Lymphoma, Mantle-Zone; Lymphomas, Centrocytic Small-Cell; Lymphomas, Mantle-Cell; Lymphomas, Mantle-Zone; Mantle Cell Lymphoma; Mantle Zone Lymphoma; Mantle-Cell Lymphomas; Mantle-Zone Lymphomas; Small-Cell Lymphoma, Centrocytic; Small-Cell Lymphomas, Centrocytic; Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated; Lymphoma, Centrocytic Small-Cell; Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated; Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated; Lymphoma, Lymphocytic, Intermediate; Lymphoma, Small-Cell, Centrocytic; Mantle-Zone Lymphoma

Networked: 1519 relevant articles (121 outcomes, 239 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Lymphoma (Lymphomas)
2.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
3.	Non-Hodgkin Lymphoma (Lymphosarcoma)
4.	Neoplasms (Cancer)
5.	Multiple Myeloma

Experts

1.	Dreyling, Martin: 43 articles (11/2015 - 02/2003)
2.	Campo, Elias: 27 articles (08/2015 - 01/2002)
3.	Wang, Michael: 24 articles (06/2014 - 02/2005)
4.	Colomer, Dolors: 23 articles (11/2015 - 11/2004)
5.	Medeiros, L Jeffrey: 22 articles (09/2013 - 05/2002)
6.	Hiddemann, Wolfgang: 20 articles (02/2015 - 02/2003)
7.	Lai, Raymond: 20 articles (08/2013 - 12/2002)
8.	Rosenwald, Andreas: 19 articles (11/2015 - 11/2005)
9.	Kahl, Brad S: 18 articles (09/2015 - 10/2005)
10.	Ott, German: 17 articles (11/2015 - 10/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mantle-Cell Lymphoma:

1.	rituximab (Mabthera)FDA Link 05/01/2005 - "Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy." 09/24/2015 - "Rituximab maintenance results in improved progression-free survival but has not yet shown to improve overall survival in mantle cell lymphoma (MCL), but given the poor prognosis with post auto-HCT failure in MCL, maintenance rituximab can be considered on a case-by-case basis. " 08/09/2012 - "R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. " 12/01/2008 - "Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. " 08/01/2012 - "We retrospectively analyzed 44 patients undergoing first-line treatment for mantle cell lymphoma with R-HyperCVAD, with or without rituximab (R) maintenance or auto-SCT. "
2.	bortezomib (Velcade)FDA Link 11/01/2015 - "Although most of the mantle cell lymphoma (MCL) patients initially responded well to bortezomib (BTZ), the dose-dependent toxicities have greatly limited the application of BTZ to MCL. " 01/01/2008 - "Single-agent bortezomib is effective in several lymphoid malignancies, and is recommended for second-line treatment of mantle-cell lymphoma (MCL). " 11/10/2015 - "Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance." 02/01/2005 - "Encouraging activity has been demonstrated with bortezomib in the first-line treatment of myeloma and in patients with mantle cell lymphoma. " 04/01/2009 - "The recent approval of bortezomib for the treatment of mantle cell lymphoma (MCL) by the US Food and Drug Administration is based on the results of the multicentre PINNACLE study with supportive data from a number of single and multicentre Phase 2 studies. "
3.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/01/2015 - "Treatment associated Mantle Cell Lymphoma with Cyclophosphamide therapy for Granulomatosis with Polyangiitis." 03/01/2015 - "We present a case of a 68-year-old woman who developed mantle cell lymphoma in the setting of long-term cyclophosphamide therapy and relapsing granulomatosis with polyangiitis (Wegener's granulomatosis, GPA). " 05/01/2002 - "High-dose treatment with (131)I-Tositumomab, etoposide, and cyclophosphamide results in a high remission rate and may provide long-term disease-free survival for patients with relapsed or refractory mantle cell lymphoma." 02/01/2006 - "Bendamustine can efficaciously and safely replace cyclophosphamide, as used in standard COP therapy, for the treatment of patients with indolent NHL and mantle cell lymphoma. " 09/01/2001 - "Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma."
4.	bendamustine FDA Link 12/01/2015 - "Bendamustine is effective in B-cell malignancies, including mantle cell lymphoma (MCL), alone and in combination with other agents. " 07/01/2015 - "This study was a postapproval commitment to investigate bendamustine's effect on cardiac repolarization in treatment-naïve adults with advanced indolent NHL/mantle cell lymphoma (MCL). " 09/01/2010 - "In this multicenter phase II trial, the efficacy and safety of bendamustine were evaluated in Japanese patients with relapsed or refractory indolent B-NHL or mantle-cell lymphoma (MCL). " 12/01/2015 - "Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line." 09/01/2014 - "Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience."
5.	lenalidomide (CC 5013)FDA Link 09/01/2009 - "Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma." 08/01/2015 - "Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial." 06/01/2014 - "Data from preclinical studies paved the way for clinical trials of lenalidomide in mantle cell lymphoma (MCL). " 11/01/2013 - "Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study." 10/01/2012 - "Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences."
6.	Cytarabine (Cytosar-U)FDA LinkGeneric 07/30/2015 - "High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma." 02/01/2009 - "High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients." 07/30/2015 - "We revisited the prognostic value of frequently detected somatic gene copy number alterations (CNAs) in mantle cell lymphoma (MCL) patients treated first line with immunochemotherapy and autologous stem cell transplantation (ASCT), with or without high-dose cytarabine, in the randomized European MCL Younger trial. " 02/01/2008 - "It is more effective when used in combination with chemotherapy such as R-CHOP, R-hyperCVAD/MTX-Ara-C, or R-FCM as front-line or salvage therapy for mantle cell lymphoma. " 05/01/2009 - "A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study."
7.	Vincristine (Oncovin)FDA LinkGeneric 06/01/2013 - "Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine." 03/01/2009 - "In spite of the general poor prognosis of mantle cell lymphoma, our patient had a good clinical and endoscopic response to the standard cyclophosphamide, vincristine, prednisone (CVP) therapy. " 06/01/2004 - "This cell line was used as a model to investigate the activity of the three drugs doxorubicin, cyclophosphamide and vincristine, commonly used in the treatment of mantle cell lymphoma patients. " 02/01/2014 - "Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy." 03/01/2012 - "Among these are vincristine sulfate, a mitotic inhibitor used to treat a variety of leukemias, lymphomas, and other cancers, and bortezomib, a 26S proteasome inhibitor used primarily to treat relapsed multiple myeloma and mantle cell lymphoma. "
8.	Doxorubicin (Adriamycin)FDA LinkGeneric 06/01/2004 - "This cell line was used as a model to investigate the activity of the three drugs doxorubicin, cyclophosphamide and vincristine, commonly used in the treatment of mantle cell lymphoma patients. " 03/01/2010 - "Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma." 12/01/2000 - "The regimen of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) has demonstrated significant activity in adult lymphocytic leukemia (ALL) and in other hematologic malignancies, including Burkitt's disease, lymphoblastic lymphoma, mantle cell lymphoma, and multiple myeloma. " 03/01/2002 - "To evaluate the efficacy of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) induction therapy in patients with newly diagnosed mantle-cell lymphoma (MCL). " 06/01/2012 - "Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS."
9.	Proteasome Endopeptidase Complex (Proteasome)IBA 01/01/2006 - "Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas." 06/01/2012 - "Proteasome inhibitors in mantle cell lymphoma." 02/01/2006 - "Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach." 07/01/2003 - "Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells." 07/06/2011 - "Proteasome inhibitors have demonstrated clinical efficacy in the treatment of multiple myeloma and mantle cell lymphoma and are under evaluation for the treatment of other malignancies. "
10.	Prednisone (Sone)FDA LinkGeneric 03/01/2009 - "In spite of the general poor prognosis of mantle cell lymphoma, our patient had a good clinical and endoscopic response to the standard cyclophosphamide, vincristine, prednisone (CVP) therapy. " 03/05/2015 - "In this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). " 03/01/2008 - "The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed at our center to treat 22 patients with heavily pretreated, recurrent mantle cell lymphoma (MCL). " 02/01/2006 - "The purpose of this study was to compare the efficacy and toxicity of bendamustine, vincristine + prednisone (BOP) with a standard regimen of cyclophosphamide, vincristine + prednisone (COP) in patients with previously untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma. " 02/01/2006 - "Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)."

Therapies and Procedures

1.	Stem Cell Transplantation 10/10/2013 - "Although dose-intensive strategies or high-dose therapy induction followed by autologous stem-cell transplantation have improved the outcome for patients with mantle-cell lymphoma (MCL), most eventually relapse and subsequently respond poorly to additional therapy. " 04/01/2005 - "Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network." 03/15/2006 - "Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma." 05/01/2002 - "Relapsed mantle cell lymphoma is a radiation-sensitive malignancy that is unlikely to be cured by treatment with conventional high-dose therapy and autologous stem cell transplantation. " 02/01/2000 - "This study was designed to evaluate the efficacy of therapeutic intensification with autologous stem cell transplantation (ASCT) for mantle cell lymphomas (MCL) in terms of response rate, duration of response, and event-free and overall survivals. "
2.	Drug Therapy (Chemotherapy) 01/01/1998 - "In advanced stage mantle cell lymphoma, conventional chemotherapy yields a complete remission rate below 40%, and the median survival rate is only about 3 years. " 05/02/2007 - "In patients with indolent or mantle cell lymphoma, R-chemo is superior to chemotherapy alone with respect to overall survival." 01/01/2011 - "A second patient, a woman aged 79 years, with a history of leukaemic mantle cell lymphoma, was treated with poly-chemotherapy (R-CHOP), after which remission was achieved. " 09/01/2005 - "We assessed immune responses to a well-characterized idiotype vaccine in individuals with severe B-cell depletion but normal T cells after CD20-specific antibody-based chemotherapy of mantle cell lymphoma in first remission. " 07/15/2003 - "Mantle cell lymphoma (MCL) is rarely cured with standard-dose chemotherapy. "
3.	Transplants (Transplant) 01/01/2003 - "Results from these studies suggest that indications for allogeneic transplant include patients with low-grade NHL with a sibling or matched donor who are under 60 years of age; young patients with mantle cell lymphoma who are in first remission and have a sibling or matched donor; patients with high-grade NHL who have already failed an autograft but have chemosensitive disease, and those under 30 years of age who have poor-risk disease and are in first remission. " 05/08/2014 - "Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma." 11/01/2001 - "In the absence of clear evidence for a survival advantage for patients receiving stem cell transplants for mantle cell lymphoma, entry into clinical trials should be a priority." 08/01/2014 - "Transmission of t(11;14)-positive cells by allogeneic stem cell transplant: 10-year journey to mantle cell lymphoma." 09/01/2013 - "We classified pre-transplant PET/CT performed before auto-SCT as positive or negative to evaluate the impact of pre-transplant PET/CT in mantle cell lymphoma (MCL). "
4.	Transplantation (Transplant Recipients) 01/01/2005 - "The benefit of autologous or allogeneic BMT for mantle cell lymphoma is thus most apparent when transplantation is performed in first remission. " 11/01/2001 - "Optimal first-line regimens for mantle cell lymphoma have yet to be defined, and it is therefore difficult to place the role of first remission transplantation in an appropriate context. " 08/01/1996 - "Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma." 04/30/2009 - "In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential transplantation protocols. " 02/01/1999 - "The results of transplantation trials for these patients are also confounded by the relatively short follow-up intervals in low-grade NHL and small patient numbers in studies of transplantation for less common NHL subtypes, such as lymphoblastic, Burkitt's, and mantle cell lymphomas. "
5.	Autologous Transplantation 02/01/2001 - "Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting." 06/01/2012 - "Autologous transplantation and management of younger patients with mantle cell lymphoma." 10/01/2008 - "Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma." 03/01/2004 - "This review focuses on recent advances in allogeneic and autologous transplantation for mantle cell lymphoma. " 09/01/2000 - "AlloSCT may offer a useful approach in a subgroup of patients with mantle-cell lymphoma who have relapsed after autologous transplantation."